Search for: "Lisa Ouellette"
Results 41 - 60
of 173
Sort by Relevance
|
Sort by Date
24 Jun 2020, 5:36 pm
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob S. [read post]
22 Jun 2020, 11:45 am
Sachs on Reimbursement Policy and Innovation Incentives for COVID-19 July 23: Lisa Larrimore Ouellette on Innovation Policy Pluralism and COVID-19. [read post]
18 Jun 2020, 1:23 pm
Sherkow, Lisa Larrimore Ouellette, Nicholson Price, and Rachel SachsIn the United States, one of the most important factors in receiving COVID-19 testing or treatment is access to insurance. [read post]
16 Jun 2020, 6:57 am
Guest post by Jake Linford, Loula Fuller and Dan Myers Professor, Florida State University College of Law, whose trademark law scholarship I have highlighted on JotwellI want to thank Lisa Ouellette for inviting me to blog about United States Patent & Trademark Office v. [read post]
11 Jun 2020, 2:30 pm
Sherkow, Lisa Larrimore Ouellette, and Nicholson PriceOver the past two weeks, the United States—already hit hard by the COVID-19 pandemic—has reckoned with another public health crisis: police violence against Black Americans. [read post]
27 May 2020, 12:00 pm
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob S. [read post]
20 May 2020, 1:58 pm
Guest Post by Colleen V. [read post]
19 May 2020, 3:30 pm
Sherkow, Lisa Larrimore Ouellette, Nicholson Price, and Rachel SachsLast week, we focused on incentives for developing clinical evidence supporting the use of remdesivir for COVID-19 and analyzed the FDA’s grant of an emergency use authorization (EUA) for the drug. [read post]
12 May 2020, 7:49 am
Sherkow, Lisa Larrimore Ouellette, and Nicholson PriceThe antiviral drug remdesivir, developed by California-based biopharmaceutical company Gilead Sciences in collaboration with government scientists, has emerged as the new standard of care for COVID-19 patients. [read post]
27 Apr 2020, 1:27 pm
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob SherkowHealth systems worldwide are facing shortages of crucial medical supplies, including personal protective equipment (PPE), diagnostic testing components including kits and nasal swabs, and even ventilators or ventilator parts. [read post]
24 Apr 2020, 6:58 am
As Daniel Hemel and Lisa Ouellette have written, “[g]overnments can offer strong incentives to drug makers while ensuring affordability by committing to patent buyouts for effective treatments. [read post]
21 Apr 2020, 2:09 pm
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob SherkowOur recent posts have highlighted shortages in three COVID-19-related knowledge goods: testing, drugs (such as those needed to put patients on ventilators), and clinical trial information about effective treatments. [read post]
15 Apr 2020, 8:14 am
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob SherkowIt’s now clear that expansive, population-wide testing is part-and-parcel of every successful COVID-19 containment strategy. [read post]
8 Apr 2020, 3:37 pm
Daniel Hemel is an assistant professor at the University of Chicago Law School and Lisa Larrimore Ouellette is an associate professor at Stanford Law School. [read post]
8 Apr 2020, 9:18 am
Daniel Hemel on the Role of the Private Sector in Battling COVID-19 willcanderson Wed, 04/08/2020 - 11:18 Read more about Daniel Hemel on the Role of the Private Sector in Battling COVID-19 The New York Times Daniel Hemel Lisa Larrimore Ouellette COVID-19 Pharmaceutical Profits and Public Health Are Not Incompatible [read post]
7 Apr 2020, 7:34 am
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob SherkowThe escalating pandemic has caused devastating shortages not only of ventilators and personal protective equipment like masks, but also of essential medicines needed to treat COVID-19 patients. [read post]
30 Mar 2020, 8:40 am
By Lisa Larrimore Ouellette, Nicholson Price, Rachel Sachs, and Jacob SherkowOne of the dizzying stream of innovation and health law stories to emerge last week is Oracle’s partnership with the White House to study unproven pharmaceuticals for treating COVID-19. [read post]
29 Mar 2020, 7:56 pm
Professor Lisa Larrimore Ouellette has an excellent analysis of the situation, here. [read post]
17 Mar 2020, 10:29 am
But I initially encountered it when the authors presented an early draft at the 2012 Yale Law School Information Society Project's "Innovation Beyond IP Conference," conceived and brought together by Amy Kapczynski and Written Description's Lisa Ouellette. [read post]
16 Mar 2020, 5:04 pm
The article draws on the expertise of four professors, Ana Santos Rutschman, Lisa Larrimore Ouellette, Mark Cohen and Jacob Sherkow. [read post]
